Orally disintegrating drug carriers for paediatric pharmacotherapy

Emma A. Kean, Oluwatoyin A. Adeleke*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

9 Citations (Scopus)

Abstract

Non-compliance, dosing inaccuracy, choking risk, flavour, and instability, are some of the issues associated with paediatric, oral dosage forms — tablets, capsules, solutions, and suspensions. Orally disintegrating drug carriers, a dosage form with growing interest, are thought to overcome several of the challenges associated with these conventional formulations by rapidly disintegrating within the buccal cavity without the need for water. This review serves as an up-to-date report on the various types of orodispersible delivery systems, currently being developed or commercialized, by detailing their characteristics, manufacturing processes, and applications in the paediatric population. Mentioned are orodispersible tablets, films, wafers and lyophilisates, mini-tablets, capsules, granules, electrospun fibers and webs. Also highlighted are the choice of excipients, quality control requirements, and expected pharmacokinetics of orally disintegrating drug carriers concerning the paediatric population. Overall, orodispersible formulations, particularly tablets, films, and lyophilisates/wafers, have shown to be a valuable addition to medication administration in minors, thus the execution of more targeted research and development activities is expected to lead to enhanced paediatric care and outcomes.

Original languageEnglish
Article number106377
JournalEuropean Journal of Pharmaceutical Sciences
Volume182
DOIs
Publication statusPublished - 1 Mar 2023
Externally publishedYes

Keywords

  • Child-appropriate dosage forms
  • Excipients
  • Manufacturing processes
  • Orally disintegrating drug carriers
  • Orodispersible drug delivery systems
  • Orodispersible drug formulations
  • Paediatric medicines

Fingerprint

Dive into the research topics of 'Orally disintegrating drug carriers for paediatric pharmacotherapy'. Together they form a unique fingerprint.

Cite this